Literature DB >> 11468939

Assessment of actual significance levels for covariate effects in NONMEM.

U Wählby1, E N Jonsson, M O Karlsson.   

Abstract

The objectives of this study were to assess the difference between actual and nominal significance levels, as judged by the likelihood ratio test, for hypothesis tests regarding covariate effects using NONMEM, and to study what factors influence these levels. Also, a strategy for obtaining closer agreement between nominal and actual significance levels was investigated. Pharmacokinetic (PK) data without covariate relationships were simulated from a one compartment i.v. bolus model for 50 individuals. Models with and without covariate relationships were then fitted to the data, and differences in the objective function values were calculated. Alterations were made to the simulation settings; the structural and error models, the number of individuals, the number of samples per individual and the covariate distribution. Different estimation methods in NONMEM were also tried. In addition, a strategy for estimating the actual significance levels for a specific data set, model and parameter was investigated using covariate randomization and a real data set. Under most conditions when the first-order (FO) method was used, the actual significance level for including a covariate relationship in a model was higher than the nominal significance level. Among factors with high impact were frequency of sampling and residual error magnitude. The use of the first-order conditional estimation method with interaction (FOCE-INTER) resulted in close agreement between actual and nominal significance levels. The results from the covariate randomization procedure of the real data set were in agreement with the results from the simulation study. With the FO method the actual significance levels were higher than the nominal, independent of the covariate type, but depending on the parameter influenced. When using FOCE-INTER the actual and nominal levels were similar. The most important factors influencing the actual significance levels for the FO method are the approximation of the influence of the random effects in a nonlinear model, a heteroscedastic error structure in which an existing interaction between interindividual and residual variability is not accounted for in the model, and a lognormal distribution of the residual error which is approximated by a symmetric distribution. Estimation with FOCE-INTER and the covariate randomization procedure provide means to achieve agreement between nominal and actual significance levels.

Mesh:

Substances:

Year:  2001        PMID: 11468939     DOI: 10.1023/a:1011527125570

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  10 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

3.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

4.  Automated covariate model building within NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

5.  Three new residual error models for population PK/PD analyses.

Authors:  M O Karlsson; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

Review 6.  The use of population pharmacokinetics in drug development.

Authors:  S Vozeh; J L Steimer; M Rowland; P Morselli; F Mentre; L P Balant; L Aarons
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

7.  A note on confidence intervals with extended least squares parameter estimates.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

8.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

9.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

Review 10.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982
  10 in total
  128 in total

1.  Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences.

Authors:  Jogarao V S Gobburu; John Lawrence
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

2.  Population pharmacokinetics of carbamazepine in elderly patients.

Authors:  Baralee Punyawudho; Eugene R Ramsay; Richard C Brundage; Flavia M Macias; Joseph F Collins; Angela K Birnbaum
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

3.  Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.

Authors:  Thomas Kerbusch; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

4.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

5.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

6.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

7.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

8.  Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

Authors:  Ulrika Wählby; Katalin Matolcsi; Mats O Karlsson; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

9.  Design of pharmacokinetic studies for latent covariates.

Authors:  Chakradhar V Lagishetty; Carolyn V Coulter; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-10       Impact factor: 2.745

10.  Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers.

Authors:  Carol Cronenberger; Diane R Mould; Hans-Juergen Roethig; Mohamadi Sarkar
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.